New York, May 19, 2026 – Shares of Amesite Inc. skyrocketed in premarket trading Tuesday after the artificial intelligence software company announced its largest-ever enterprise deployment for the NurseMagic product. The stock, which closed Monday at $0.7861, was indicated at $2.50 just before 5 a.m. EDT, representing a gain of approximately 218%.
Contract Details
The company disclosed that an undisclosed home-care client plans to roll out NurseMagic's AI-powered documentation tools across its workforce, which manages 2,700 patients. The deployment will integrate with both an electronic medical records (EMR) system and electronic visit verification (EVV) technology used to confirm home-care visits.
While the announcement marks a significant milestone for the microcap firm, Amesite did not reveal the contract's financial terms, including revenue contribution, margins, duration, or the customer's identity. The lack of specific details leaves investors to gauge the deal's impact based on scope alone.
Management Commentary
Dr. Ann Marie Sastry, Amesite's chief executive officer, stated that the deployment “validates the strength of our architecture.” Sarah Berman, principal finance and accounting officer, emphasized the company’s “same financial discipline,” while Madison Bush, director of corporate operations, noted a “growing volume of inbound interest.”
Financial Snapshot
The news came on the heels of Amesite's quarterly earnings report for the period ended March 31. Revenue for the quarter reached $83,332, up from $30,690 in the same period a year earlier. However, the net loss widened to $678,061 compared to a loss of $663,418 last year. For the nine-month period, revenue totaled $285,678, a significant increase from $54,700 in the prior year, while operating expenses declined to $2.38 million from $2.80 million.
As of March 31, cash and restricted cash stood at $740,711, before the company completed a registered direct offering and private placements on April 28, generating approximately $2.2 million in net proceeds. Despite this infusion, Amesite's latest filing with the Securities and Exchange Commission included language expressing “substantial doubt” about the company's ability to continue as a going concern.
Market Context and Risks
The premarket rally reflects investor optimism that the NurseMagic platform can gain traction in the non-acute and home-care segments, a niche that differentiates Amesite from competitors like Abridge and Suki, which focus primarily on hospital physician notes. However, the stock's volatility in light trading volumes and the absence of key contract details pose clear risks.
Analysts caution that without recurring revenue from the new client, the company may need additional capital, potentially diluting existing shareholders. The going concern warning underscores the financial strain, even as the company's cash position has been bolstered by the April financing.
Outlook
With regular Nasdaq trading set to begin Tuesday, the stock's first move at the open will provide a clearer picture of investor sentiment. The broader market remains open, with the next closure scheduled for Memorial Day on May 25. For Amesite, the NurseMagic deployment represents a pivotal opportunity, but the path to profitability remains uncertain.
